Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency Testing in 2-3 Months
The next step is to check G6PD enzyme levels in 2-3 months (Option B). This patient has clear evidence of non-immune hemolysis (low haptoglobin, elevated LDH, reticulocytosis, negative DAT) that occurred in the context of diabetic ketoacidosis, and DKA is a well-documented trigger for unmasking G6PD deficiency 1, 2, 3.
Why G6PD Testing Must Be Delayed
Testing must be delayed because reticulocytosis causes false-negative G6PD results. The patient's reticulocyte count of 4.5% indicates a robust bone marrow response with young red blood cells that contain higher enzyme levels than older cells 4. Since G6PD deficiency results from unstable enzymes that decline as red cells age, testing during active hemolysis with reticulocytosis will miss the diagnosis 4.
- The American Journal of Hematology consensus recommends accounting for red cell age when interpreting G6PD results, particularly when reticulocytosis is present 4
- Young circulating erythrocytes may contain normal or near-normal enzyme levels despite underlying G6PD deficiency 4
- Testing should occur 2-3 months after the hemolytic episode when the reticulocyte count normalizes and the red cell population reflects steady-state enzyme activity 4
Clinical Evidence Supporting G6PD Deficiency
This presentation is classic for G6PD deficiency unmasked by DKA. Multiple case reports document this exact scenario:
- DKA can trigger hemolytic crises in G6PD-deficient patients through oxidative stress mechanisms 1, 2, 3
- The combination of hemolysis (low haptoglobin 8, elevated LDH 550) with reticulocytosis (4.5%) and negative DAT points to a non-immune corpuscular hemolytic anemia 5, 6
- The normal peripheral smear (no spherocytes, target cells, or other morphologic abnormalities) makes membranopathies and hemoglobinopathies less likely 5, 6
- G6PD deficiency has 10% prevalence in African-American males and up to 35% in parts of Africa, making it a common undiagnosed condition 3
Why Other Options Are Incorrect
No additional testing (Option A) is inappropriate because the hemolysis requires explanation and G6PD deficiency has significant implications for future medication choices and oxidative stress avoidance 4.
B12 testing (Option C) is not indicated because the patient has normocytic anemia without macrocytosis, and the reticulocytosis indicates appropriate bone marrow response rather than megaloblastic dysfunction 4.
Hemoglobin electrophoresis (Option D) is unnecessary because the peripheral smear shows no target cells, microcytosis, or other features of hemoglobinopathies like sickle cell disease or thalassemia 4, 5.
Bone marrow biopsy (Option E) is not warranted because the reticulocytosis demonstrates intact marrow function and appropriate response to hemolysis 4, 6. Bone marrow evaluation is reserved for pancytopenia or inadequate reticulocyte response 4.
Critical Management Points
Avoid precipitating factors once G6PD deficiency is confirmed. The patient should avoid:
- Oxidative medications (dapsone, sulfonamides, nitrofurantoin, primaquine, rasburicase) 4
- Fava beans and other known triggers 2, 6
- Methylene blue treatment if future methemoglobinemia occurs, as it worsens G6PD-related hemolysis 4
First-degree relatives should be tested because G6PD deficiency is X-linked and family screening identifies at-risk individuals 4.
Document the diagnosis clearly to prevent future exposure to hemolytic triggers and ensure appropriate perioperative planning 4.